Navigating a Challenging Phase: Novo Nordisk’s Strategic Defense

Novo Nordisk finds itself preparing for a period of intensified competition. At the recent J.P. Morgan Healthcare Conference, CEO Mike Doustdar took the opportunity to temper expectations, signaling that 2026 is unlikely to be a straightforward year for the Danish pharmaceutical giant. The primary headwinds include mounting competitive pressures, the expiration of key market exclusivities, and the formidable presence of rival Eli Lilly, which is capturing market share across an increasing number of territories.

Doustdar explicitly identified U.S.-based Eli Lilly as the most significant competitive threat in several regions. In response, Novo Nordisk is deploying a three-pronged strategic defense. This plan involves expanding manufacturing capacity, developing higher-dose versions of existing treatments, and launching new products. A notable recent addition is the oral formulation of Wegovy, which has just received regulatory approval.

This pill could prove transformative. A partnership with Amazon Pharmacy, announced in early January, grants Novo Nordisk access to a network of over 70,000 U.S. pharmacies and established telemedicine platforms. By eliminating the needle—a common barrier for patients—the tablet version is anticipated by analysts to significantly broaden the eligible patient pool.

The CEO's Candid Assessment and Market Shifts

The company's chief executive was forthright in his commentary: maintaining exceptionally high market shares inevitably invites competition to capture a portion of them. This dynamic is particularly relevant in international markets, where Novo Nordisk has historically dominated but now faces the expiry of crucial patent protections. The firm operates in 80 to 85 countries and must brace for a more challenging environment.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

While Doustdar asserted that Novo remains "structurally well-positioned" outside the United States, he acknowledged the evolving landscape of the obesity drug market. The rise of online distribution and cross-border trade is lowering barriers to entry, making it easier for competitors to establish a foothold.

Valuation and Pipeline Under Scrutiny

From a valuation perspective, Novo Nordisk's shares currently trade at a forward P/E ratio of approximately 17. This figure sits notably below its own historical averages and beneath the valuation multiple assigned to Eli Lilly. Despite pricing pressures within the obesity segment, the company's EBITDA margin remains robust at over 47%.

The Wall Street consensus currently rates the stock as a "Moderate Buy," with price targets extending as high as $73.50. Chinese investment bank CICC initiated coverage on January 9 with an "Outperform" rating. Justifying these expectations will fall to the company's development pipeline. Chief Scientific Officer Martin Holst Lange confirmed at the conference that Novo's focus remains firmly on metabolic diseases. The drug candidate CagriSema was submitted for FDA approval in December, and additional triple-agonist therapies are in development.

The coming months will reveal whether these strategic initiatives are sufficient for Novo Nordisk to defend its leading market position.